US Bioscience

US Bioscience Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 2

US Bioscience General Information

Description

Developer and manufacturer of drugs intended for cancer and AIDS treatment. The company's drugs include medicine which is approved for the reduction of cumulative kidney toxicity associated with repeated administration of cisplatin enabling patients with advanced ovarian cancer and non-small cell lung cancer to heal quickly.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 100 Front Street
  • Conshohocken, PA 19428
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

US Bioscience Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore US Bioscience‘s full profile, request access.

Request a free trial

US Bioscience Executive Team (1)

Name Title Board Seat Contact Info
C. Clarke President & Chief Executive Officer

US Bioscience Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore US Bioscience‘s full profile, request access.

Request a free trial